Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB033 dose-ranging study with Avonex in active relapsing multiple sclerosis
NL-OMON38864Phase 2Active, not recruiting
- Sponsor
- Biogen
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of opicinumab in multiple sclerosis (MS) (5 arms), sponsored by Biogen. Primary endpoint: Confirmed improvement of neuro-physical and/or cognitive function composite. Started Aug 2013; status: active, not recruiting.
02
Drugs
opicinumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON38864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38864.